News blog

IXICO

  • BY: Andrew Hore |
  • POSTED: 12/08/2019 |

Neuroscience-focused digital data analysis technology developer IXICO has signed two new biopharmaceutical client contracts worth a total of more than £1m.

An ongoing phase III study has been extended and this will add £900,000 to the contract value.

One study has been discontinued following an interim review of data. It will not affect revenue this year, but contracted revenues of £3.5m were expected up until 2025. 

© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

News Blog
All micro news

Quoted Micro 9 December 2019

Continue reading... | 10/12/2019

Omega Diagnostics

Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test. 

Continue reading... | 10/12/2019

Tricorn

House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000. 

Continue reading... | 10/12/2019

Evgen Pharma

Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment. 

Continue reading... | 10/12/2019

All micro news

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds